We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience.

Skip to main content

Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

- Chemotherapy-induced Neutropenia
- Completed

Study Title: Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel

Teva Identifier: NEUGR-002

ClinicalTrials.gov Identifier: NCT00837265

Study Status: Completed

Trial Condition(s): Chemotherapy-induced Neutropenia

Interventions: Biological: Neugranin | Drug: Pegfilgrastim | Drug: Chemotherapy

Study Description: Please refer to ClinicalTrials.gov for a description of the trial

Click for participation criteria and map of study locations

cancer icon for clinical trials

Key Participation Requirements

Gender: Female, Male

Age Range: 18 Years and older

Trial Duration: 08/01/2008 - 07/01/2010

Phase: Phase 2/3

Study Type

Interventional